Adaptimmune Therapeutics, which operates in Oxford, UK, announced business developments regarding its cell therapies and debt facilities.
4 reports, 2 independent
Updated Aug 13
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Adaptimmune Therapeutics, which operates in Oxford, UK, announced business developments regarding its cell therapies and debt facilities.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Adaptimmune sold cell therapies to US WorldMeds and repaid debt facilities with Hercules Capital.1 source
- Adaptimmune Therapeutics received a rating downgrade due to solvency concerns.
Keep exploring
The entities involved
-
Adaptimmune Therapeutics
biopharmaceutical company
Nothing else this week.
-
Oxford
city in Oxfordshire, England
Coverage
Newest first; wire copies grouped- NewsfileAdaptimmune Reports Q2 Financial Results and Provides Business Update Q2 Tecelra sales of $11.1m with 16 patients invoiced represents >150% growth vs Q1 2025 Entered into a definitive agreement for t
- PR NewswireUS WorldMeds Completes Acquisition of Adaptimmune's Cell-Therapy Portfolio; Ensures Continued Patient Access to Tecelra and Advances Development of lete-cel LOUISVILLE, Ky., Aug. 4, 2025 /PRNewswire/
- NewsfileAdaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds Tecelra will continue to be available to patients without int
- Unknown outlet